Industry Associations & Lobby Groups

US professional psychiatric body that publishes position statements and guidance relevant to evidence standards and clinical policy considerations for psychedelic and empathogenic therapies.

The International Alliance of MDMA Practitioners (MDMA Alliance) is a professional network focused on standards, training, and shared learning for MDMA-assisted therapy practitioners and allied clinicians.

Nonprofit organizer and host of the Psychedelic Science conference series, alongside broader educational and policy programming.

Psychedelic Coalition for Health (PCH) is a clinician-led psychedelic medicine education and advocacy organization co-founded by psychotherapists Lauren Taus and Nicholas Brüss, offering psychedelic-assisted therapy training, virtual symposia, and scholarship programs for healthcare professionals. PCH trains licensed clinicians in ketamine, MDMA, and IFS-informed approaches while advocating for equitable access to and responsible implementation of psychedelic medicine.

Washington, D.C.-based nonprofit advocacy organization focused on federal and state psychedelic policy, lawmaker education, and coalition-building for safe and equitable access.

US political action organization supporting candidates and policy movements that advance evidence-based psychedelic medicine access and rescheduling at state and federal levels.

European advocacy platform convening policymakers, regulators, researchers, and businesses to develop EU regulatory pathways for psychedelic therapies.